ClinicalTrials.gg
CompletedNCT02173249Updated Sep 14, 2017

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

A Phase 1 interventional study of AC 170 0.24% in Healthy, sponsored by Aciex Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-09-14.

Sponsored by Aciex Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Aciex Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 18 and no older than 55 years of age
  • be able to self-administer eye drops or have a parent/legal guardian available for this purpose
  • have blood and urine analysis within normal limits
  • have ocular health within normal limits

Exclusion criteria

Exclusion Criteria:

  • known or sensitivities to the study medication or its components
  • have any active systemic or ocular disorder (other than refractive disorder)
  • have inability to comply with controlled diet
  • have used prescription or non prescription drugs within and throughout study
  • have used alcohol or tobacco within the washout period
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    AC 170 0.24%

    Drug: AC 170 0.24%

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax values of AC 170 0.24%

    Plasma samples will be drawn at specified time points and then analyzed to determine Cmax values of AC 170 0.24% in the plasma

    Time frame: 1 week

  2. Tmax values of AC 170 0.24%

    Plasma samples will be drawn at specified time points and then analyzed to determine Tmax values of AC 170 0.24% in the plasma

    Time frame: 1 week

  3. AUC values of AC 170 0324%

    Plasma samples will be drawn at specified time points and then analyzed to determine AUC values of AC 170 0.24% in the plasma

    Time frame: 1 week

  4. T 1/2 values of AC 170 0.24%

    Plasma samples will be drawn at specified time points and then analyzed to determine T 1/2 values of AC 170 0.24% in the plasma

    Time frame: 1 week

07

Study locations

1 site
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2014
First posted
Jun 24, 2014
Start
Jun 2014
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Last update
Sep 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02173249
Lead sponsor
Aciex Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Jun 2014
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Sep 14, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion